SV2A
6 drugs CNS
4
approved indications
6
Approved Drugs
4
Companies
4
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (4 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (4 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
UCB INC 3 drugs
CAPLIN 1 drug
Aurobindo Pharma 1 drug
By Therapeutic Area
Other 5 drugs
CNS 1 drugs
Drugs by Company PRO
CAPLIN 1 drug
Aurobindo Pharma 1 drug
ZYDUS PHARMS USA INC 1 drug
By Therapeutic Area
Other 5 drugs
KEPPRA, BRIVIACT, BRIVARACETAM, KEPPRA XR +1 more
CNS 1 drugs
LEVETIRACETAM IN SODIUM CHLORIDE
Indications Treated
Partial-Onset SeizuresMyoclonic SeizuresPrimary Generalized Tonic-Clonic SeizuresEpilepsy
All Drugs Targeting SV2A
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| LEVETIRACETAM IN SODIUM CHLORIDE | CAPLIN | 2011 | 4 | CNS |
| KEPPRA | UCB INC | 1999 | 3 | |
| BRIVIACT | UCB INC | 2016 | 1 | |
| BRIVARACETAM | Aurobindo Pharma | 2022 | 1 | |
| KEPPRA XR | UCB INC | 2008 | 1 | |
| LEVETIRACETAM | ZYDUS PHARMS USA INC | 2008 | - |